when did tirzepatide come out GLP-1 Genetics: How Genes Affect Appetite, Semaglutide, and Response How the weight loss drug
Description
Abstract Objective: A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM)

Note: Most individuals do NOT see significant weight loss in the first month of their GLP-1 journey

Studies show that mixing the two drugs could lead to suicide ideation or worsen suicidal thoughts

Any such offers are likely unregulated and illegal
Additionally, candidates for tirzepatide treatment need to be in good general health and willing to commit to making lifestyle changes to support their weight loss efforts

November 5, 2019
